Skip to main content Skip to search Skip to main navigation

Swissmedic: Guidance on GMP-Compliance by Foreign Manufacturers and RP Declaration

The Swissmedic Guideline on GMP-Compliance by Foreign Manufacturers was published on 1.5.2023 as version 3.0. It is addressed to the holders of marketing authorisations for medicinal products from abroad or from Switzerland if these medicinal products contain active substances from foreign manufacturers.

The guideline clarifies which documents must be submitted with the marketing authorisation application or with the notification of a change to demonstrate that the GMP conformity check has been carried out by the responsible person (RP) in accordance with Art. 11 para. 1 part i Medicinal Products Licensing Ordinance (MPLO). For this purpose an existing GMP certificate which must not be older than three years and certifies GMP conformity equivalent to Switzerland may be sufficient or if applicable a corresponding audit report.

The following amendments have been introduced:

  • Chapter 5, which deals with verifying the conformity of foreign medicinal products and active substances, now contains a hierarchy of the documents to be submitted.
  • Chapter 6 on audit reports now specifies how, when and what information must be submitted to Swissmedic.
  • In Chapter 9 on inspections by Swissmedic, it has been added that an application can be put on hold until an inspection has taken place.

The guidelines and the new form for the declaration of the RP for foreign manufacturers can be found here.


Source:

Swissmedic: News and Updates

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
Previous
Next